MOLNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

MOLECULAR PARTNERS AG

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 12, 2026

$3.66+0.10 (+2.81%)

Close on Oct 19, 2026

Earnings

Quarterly results announced on Form 8-K, Item 2.02

Quarter	Reported	Time	Revenue	EPS (GAAP)	EPS (adjusted)
Q4 FY2025 Ended Dec 31, 2025	Mar 13, 2026	Before market open	–	–	–

Company guidance

Outlook given with results on Mar 13, 2026, compared with the previous outlook

Measure	Period	Guidance	vs. prior
total operating expenses	full year 2026	45 to 55	New

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Molecular Partners filed with the SEC

Aug 25, 2026, 6:03 AM ET
Molecular Partners Reports H1 2026 Financial Results and Corporate Highlights: DLL3 Radiotherapy MP0712 Successfully Advancing to Higher Dose Level in Phase 1/2a Study
EX-99.1 to Form 6-K
Jul 20, 2026, 8:22 AM ET
Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma
EX-99.1 to Form 6-K
Jul 6, 2026, 6:00 PM ET
Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics
EX-99.1 to Form 6-K
Jul 2, 2026, 6:00 AM ET
Molecular Partners and Orano Med Announce First Patients Dosed in Phase 1/2a Trial of DLL3 Radio-DARPin MP0712
EX-99.1 to Form 6-K
Jun 1, 2026, 7:18 AM ET
Molecular Partners Holds Presentations at ASCO and SNMMI 2026 on DLL3-Targeting Radio-DARPin MP0712, Now Dosing Patients in Phase 1
EX-99.1 to Form 6-K
May 12, 2026, 4:01 PM ET
Molecular Partners Reports Financial Results and Highlights for Q1 2026, with Clinical Studies Initiated on MP0712 and MP0317
EX-99.1 to Form 6-K
May 12, 2026, 4:01 PM ET
Condensed consolidated interim financial statements (unaudited)
EX-99.2 to Form 6-K
May 1, 2026, 9:21 AM ET
Molecular Partners publishes Phase 1 MP0317 data in Nature Cancer demonstrating tumor-localized CD40 activation and tumor microenvironment remodeling
EX-99.1 to Form 6-K
Apr 14, 2026, 4:44 PM ET
Molecular Partners Announces all Board Proposals Approved, Clare Fisher Elected as New Board Member at Annual General Meeting
EX-99.1 to Form 6-K
Mar 30, 2026, 7:06 AM ET
Molecular Partners Publishes Invitation to Annual General Meeting 2026 and Proposes Clare Fisher for Election to its Board of Directors
EX-99.1 to Form 6-K
Mar 13, 2026, 1:29 PM ET
Molecular Partners Reports Highlights and Financial Results for Full Year 2025
EX-99.1 to Form 6-K
Mar 12, 2026, 4:54 PM ET
EX-99.1 to Form 6-K
EX-99.1 to Form 6-K
Feb 2, 2026, 6:54 AM ET
Molecular Partners Announces Presentation of First Imaging and Dosimetry Data of DLL3-Targeting Radiotherapy MP0712 in Patients at TWC 2026
EX-99.1 to Form 6-K
Jan 12, 2026, 5:00 PM ET
Molecular Partners Highlights Clinical Development Progress and Anticipated Milestones at 44th Annual J.P. Morgan Healthcare Conference
EX-99.1 to Form 6-K
Dec 8, 2025, 8:09 AM ET
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
EX-99.1 to Form 6-K
Nov 12, 2025, 7:38 AM ET
Molecular Partners Presents New Data for DLL3 Targeting Radiotherapy MP0712 at TRP Summit Europe 2025, Highlighting Initial Human Images and Mechanism of Action
EX-99.1 to Form 6-K
Oct 30, 2025, 4:00 PM ET
Molecular Partners Reports Q3 2025 Financial Results and Clinical Progress, with DLL3-Targeting Radio-DARPin MP0712 Phase 1 Launch Expected in 2025
EX-99.1 to Form 6-K
Aug 25, 2025, 4:01 PM ET
Molecular Partners reports financial results and highlights recent clinical pipeline progress for H1 2025
EX-99.1 to Form 6-K
Jun 12, 2025, 4:17 PM ET
Molecular Partners Announces Planned Operational Efficiencies and Extension of Cash Runway
EX-99.1 to Form 6-K
May 15, 2025, 4:01 PM ET
Molecular Partners Reports Financial Results and Highlights from Q1 2025
EX-99.1 to Form 6-K
May 15, 2025, 4:01 PM ET
Condensed consolidated interim financial statements (unaudited)
EX-99.2 to Form 6-K
Mar 6, 2025, 4:15 PM ET
Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024
EX-99.1 to Form 6-K
Mar 6, 2025, 4:02 PM ET
Zurich-Schlieren, March 6, 2025 Sincerely, Patrick Amstutz Bill Burns Chief Executive Officer Chairman of the Board 9
EX-99.1 to Form 6-K
Jan 13, 2025, 5:14 PM ET
Molecular Partners Outlines Clinical Expansion Plans and Strengthens Radiopharma Strategic Focus for 2025 at 43rd Annual J.P. Morgan Healthcare Conference
EX-99.1 to Form 6-K
Jan 13, 2025, 5:13 PM ET
Molecular Partners and Orano Med expand partnership to develop Targeted Alpha Radio-Therapies for cancer
EX-99.1 to Form 6-K
Oct 31, 2024, 4:00 PM ET
Molecular Partners Q3 2024 Interim Management Statement: Multiple Updates Across Portfolio, Radio-DARPin candidate MP0712 preparing for clinical entry, MP0533 Phase 1 on-going
EX-99.1 to Form 6-K
Oct 31, 2024, 4:00 PM ET
Condensed consolidated interim financial statements (unaudited)
EX-99.2 to Form 6-K
Oct 28, 2024, 4:05 PM ET
Molecular Partners Announces Pricing of $20 Million Underwritten Offering
EX-99.1 to Form 6-K
Oct 22, 2024, 9:02 AM ET
Molecular Partners and Orano Med Strengthen Agreement to Co-Develop 212Pb-Based Radio-DARPin Therapeutics
EX-99.1 to Form 6-K
Oct 22, 2024, 9:02 AM ET
Molecular Partners and Orano Med Present Additional Positive Preclinical Data Supporting DLL3 Targeting Radio-DARPin Therapeutic Candidate MP0712 at EANM 2024
EX-99.2 to Form 6-K
Aug 26, 2024, 4:00 PM ET
Molecular Partners Reports H1 2024 Corporate Highlights and Financials
EX-99.1 to Form 6-K
Aug 26, 2024, 4:00 PM ET
Radio-DARPin Therapy (RDT) Platform and MP0712
EX-99.2 to Form 6-K
Aug 26, 2024, 4:00 PM ET
Condensed consolidated interim financial statements (unaudited)
EX-99.3 to Form 6-K
Jun 14, 2024, 10:44 AM ET
Molecular Partners Presents Positive Preclinical Data for First Switch-DARPin Candidate MP0621 at EHA 2024
EX-99.1 to Form 6-K
Jun 14, 2024, 10:44 AM ET
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
EX-99.2 to Form 6-K
Jun 14, 2024, 10:44 AM ET
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
EX-99.3 to Form 6-K
Jun 11, 2024, 10:16 AM ET
Molecular Partners and Orano Med Share Positive Preclinical Data of their DLL3-Targeting Radio-DARPin Therapy (RDT) Candidate MP0712 at SNMMI 2024
EX-99.1 to Form 6-K
Jun 3, 2024, 5:06 PM ET
Molecular Partners Presents Positive Data From Completed Phase 1 Trial Of MP0317 (FAP X CD40 DARPin) Monotherapy In Patients With Advanced Solid Tumors At ASCO 2024
EX-99.1 to Form 6-K
May 16, 2024, 4:00 PM ET
Interim Management Statement Q1 2024 of Molecular Partners: Pipeline Progressing with Two Additional Programs to Enter the Clinic in 2025, Update to MP0533 Program
EX-99.1 to Form 6-K
May 16, 2024, 4:00 PM ET
Condensed consolidated interim financial statements (unaudited)
EX-99.2 to Form 6-K

Where these numbers come from

Parsed from the XBRL in Molecular Partners's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MOLN.

Revenue growth-100.0% · median -30.0%

Company	Revenue	Growth
GLUE	$28.73M	-83.9%
RLAY	$10.35M	+23.9%
TCRX	$7.11M	+2.2%
CRIS	$4.31M	-62.2%
MOLN	CHF 0	-100.0%
IPHA	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 34
Held by institutions: 8.9%
Auditor: KPMG AG
SEC CIK: 1745114

Advertisement
300 × 250